Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas, and Ovarian Cancers and Methods and Kits for Targeting the Antigen

a technology of mesothelium and mesothelioma, which is applied in the field of identification of specific antigens found on tumor cells, can solve the problems that antibodies to ca 125 are not useful for immunotherapy

Inactive Publication Date: 2009-11-12
THE GOVT OF THE U S A AD REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, antibodies to CA 125 are not useful for immunotherapy because the CA 125 antigen is shed into the blood stream (Bast, R., et al., N. Eng. J. Med.
Unfortunately, this protein is also abundantly expressed in kidney (Campbell, I. G., et al., Cancer Res.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas, and Ovarian Cancers and Methods and Kits for Targeting the Antigen
  • Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas, and Ovarian Cancers and Methods and Kits for Targeting the Antigen
  • Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas, and Ovarian Cancers and Methods and Kits for Targeting the Antigen

Examples

Experimental program
Comparison scheme
Effect test

examples

A. Materials and Methods

[0190]1. Cells and antibodies. Human ovarian tumor cell line, OVCAR-3, and cell lines A431, KB, MCF-7, COS-1, WI-38 and NIH 3T3 were obtained from the American Type Culture Collections (ATCC, Rockville, Md.). Cells were cultured either in RPMI 1640 or DMEM media (GIBCO Laboratories, Grand Island, N.Y.), supplemented with L-glutamine (2 mM), penicillin (50 μg / ml), streptomycin (50 units / ml) and 5-10% fetal bovine serum (GIBCO). NIH 3T3 transfectants were grown in DMEM with 0.8 mg / ml of G418 (GIBCO). Cells were used when they reached 80-90% confluency after washing three times with ice-cold PBS (GIBCO). MAb K1 and antibody MOPC-21 have been described (Chang, K., et al., Int. J. Cancer 50, 373-381 (1992)) and were used in a concentration of 5-10 μg / ml.

[0191]2. Isolation of the cDNA clones. The HeLa S3 cDNA library (ClonTech, Palo Alto, Calif.) was screened at approximately 50,000 pfu / 150 mm filter as described previously (Chang, K., and Pastan, I., Int. J. Cance...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Tmaaaaaaaaaa
temperaturesaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

This invention relates to the discovery of a differentiation antigen termed mesothelin which is associated with mesotheliomas and ovarian cancers. Mesothelin is about 69 kD in its full-length form. The invention includes uses for the amino acid and nucleic acid sequences for mesothelin, recombinant cells expressing it, methods for targeting and / or inhibiting the growth of cells bearing mesothelin, methods for detecting the antigen and its expression level as an indication of the presence of tumor cells, and kits for such detection.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 09 / 684,599, filed Oct. 5, 2000, which is a divisional of U.S. patent application Ser. No. 09 / 215,035, filed Dec. 17, 1999, now U.S. Pat. No. 6,153,430, which was a divisional of U.S. patent application Ser. No. 08 / 776,271, filed Jan. 12, 1998, now U.S. Pat. No. 6,083,502, which was a national stage application under 35 U.S.C. § 371 of PCT / US97 / 00224, filed Jan. 3, 1997, which claims priority from U.S. Provisional Application No. 60 / 010,166, filed Jan. 5, 1996. The contents of each of these applications is hereby incorporated by reference.STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT[0002]Not applicable.FIELD OF THE INVENTION[0003]This invention relates to the identification of a specific antigen found on tumor cells, particularly mesotheliomas and ovarian tumor cells and, inter alia, methods and compositions for targeting...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N1/21C07H21/04
CPCC07K14/4748
Inventor PASTAN, IRACHANG, KAI
Owner THE GOVT OF THE U S A AD REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com